SINOVAC Board Announces Status of $55.00 Special Cash Dividend Payment

SINOVAC's Board of Directors announced that the US$55.00 special cash dividend is being paid to valid shareholders who owned shares as of July 7, 2025. Record holders will receive dividend checks via FedEx or UPS, while brokers must provide a "broker letter" to receive wire payments starting July 9, 2025. Beneficial owner shareholders' accounts are expected to be credited the same day or the next business day after receiving the wire.

Title: SINOVAC Biotech Announces Special Cash Dividend Payment

SINOVAC Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has announced that its previously declared US$55.00 per common share special cash dividend is being paid to valid shareholders who owned SINOVAC shares as of the close of business on July 7, 2025 [1].

The Board of Directors of SINOVAC has confirmed that the dividend payment process is underway. For record holders listed on the Transfer Agent’s share register, dividend checks are being prepared and will be sent via FedEx or UPS on July 9, 2025, for overnight delivery if the amount to be paid is under US$100 million. If the amount exceeds US$100 million, the payment will be sent via wire transfer, and shareholders should contact the Paying Agent or Dividend Information Agent to arrange wire instructions [1].

For SINOVAC shareholders whose shares are held through a broker, their broker must fill out a "broker letter" and deliver it to the Paying Agent to facilitate the dividend payment. Beneficial owner shareholders' accounts are expected to be credited the same day or the next business day after receiving the wire payment [1].

For any questions about the dividend payment process, shareholders are encouraged to contact the Dividend Information Agent, D.F. King & Co., Inc., at sva@dfking.com, with a subject line of "Sinovac Biotech Ltd. Special Dividend" [1].

SINOVAC Biotech Ltd. continues to prioritize dividend distributions according to its previously announced policy. The company's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, and pneumococcal disease, among others [1].

References:
[1] https://www.stocktitan.net/news/SVA/sinovac-board-of-directors-provides-update-on-status-of-us-55-00-j6dorito5770.html